Business Description
Apnimed Inc
NAICS : 325412
SIC : 2836
Description
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.01 | |||||
Equity-to-Asset | -5.12 | |||||
Debt-to-Equity | -0.11 | |||||
Debt-to-EBITDA | -0.77 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -486.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.41 | |||||
Quick Ratio | 0.41 | |||||
Cash Ratio | 0.38 | |||||
Days Sales Outstanding | 9.84 | |||||
Days Payable | 146.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 82.6 | |||||
Operating Margin % | -139.91 | |||||
Net Margin % | -2.42 | |||||
EBITDA Margin % | -139.84 | |||||
FCF Margin % | -39.14 | |||||
OCF Margin % | -39.14 | |||||
ROA % | -1.02 | |||||
ROIC % | -53.85 | |||||
ROC (Joel Greenblatt) % | -5230.13 | |||||
ROCE % | -372.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 5.95 | |||||
PE Ratio without NRI | 5.91 | |||||
PS Ratio | 19.42 | |||||
EV-to-EBIT | 5.49 | |||||
EV-to-EBITDA | 5.49 | |||||
EV-to-Revenue | 11.14 | |||||
EV-to-FCF | -28.46 | |||||
Earnings Yield (Greenblatt) % | 18.21 | |||||
FCF Yield % | -3.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:APMD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Apnimed Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 96.894 | ||
| EPS (TTM) ($) | 4.726 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 51.48 | ||
| 14-Day ATR ($) | 2.73643 | ||
| 20-Day SMA ($) | 27.697 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 16.12 - 35.29 | ||
| Shares Outstanding (Mil) | 41.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Apnimed Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Apnimed Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Apnimed Inc Frequently Asked Questions
What is Apnimed Inc(APMD)'s stock price today?
The current price of APMD is $28.13. The 52 week high of APMD is $35.29 and 52 week low is $16.12.
When is next earnings date of Apnimed Inc(APMD)?
The next earnings date of Apnimed Inc(APMD) is .
Does Apnimed Inc(APMD) pay dividends? If so, how much?
Apnimed Inc(APMD) does not pay dividend.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers